Senior Scientist II - In Vitro ADME & DDI

Novartis; Basel; Vor Ort; CHF 76.000 - 142.000; Vollzeit

Benefits dieser Stelle

Hybrid working

Insurance plans

Retirement plans

Wellbeing resources

Global recognition programs

Parental leave 14 weeks

Zusammenfassung

Novartis Basel seeks a Senior Scientist II to drive in vitro ADME/DMPK projects in drug discovery. You will develop and validate advanced cell-based models (3D cultures, organoids, co-culture) and assess DDIs while contributing to strategy and data interpretation.

The role emphasizes mechanistic investigations, collaboration across multidisciplinary teams, and dissemination of findings with high scientific standards; a competitive salary and hybrid work options are offered.

Qualifikationen

• MSc or PhD in a life science discipline.
• Hands-on mammalian cell culture experience.
• Experience with advanced in vitro models (3D cultures, organoids, co-cultures).
• Strong ADME and DDIs knowledge.
• LC-MS/MS experience.
• Ability to develop and troubleshoot complex in vitro assays.
• Strong data interpretation and scientific communication.
• Collaborative work in multidisciplinary teams.

Aufgaben

• Perform existing assays and establish new methods.
• Analyze complex datasets and present outcomes.
• Support scientific strategy and candidate progression.
• Prepare technical reports and study summaries.

Kenntnisse

Cell culture

3D cultures

ADME science

LC-MS/MS

Data analysis

Scientific communication

Team collaboration

Ausbildung

MSc/PhD in life sciences

Tools

LC-MS/MS

Bioanalytical techniques

Jobbeschreibung

Novartis Basel seeks a Senior Scientist II to drive in vitro ADME/DMPK projects in drug discovery. You will develop and validate advanced cell-based models (3D cultures, organoids, co-culture) and assess DDIs while contributing to strategy and data interpretation.

The role emphasizes mechanistic investigations, collaboration across multidisciplinary teams, and dissemination of findings with high scientific standards; a competitive salary and hybrid work options are offered.